🎯 3 free searches remaining
Cannara Biotech Inc. specializes in the indoor cultivation, processing, and sale of cannabis and cannabis-derived products in Canada. The company shows strengths in liquidity with a current ratio of 2.70 and manageable debt levels (Debt/Equity of 0.31), indicating financial stability. However, concerns arise from low profitability metrics, such as a net margin of only 3.5% and a modest ROE of 0.9%. Despite a decent gross margin of 37.2%, the overall financial performance suggests potential challenges in scaling profitability, which may affect valuation moving forward.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Exceptional revenue growth of 29.0% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 6.8 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 5.9pp, demonstrating strong operational leverage.
Both gross margin (+6.8pp) and operating margin (+5.9pp) are expanding simultaneously, indicating the company is scaling profitably.
Operating cash flow surged 37.6% YoY, indicating strong cash generation capability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.